result guidanc chang overal invest thesi
dec upgrad share overweight equal weight base
view share check lot box head last minut gift idea
upgrad overweight continu believ share attract
valu favor risk/reward profil share seem resili opioid
talc headlin sign much discount may built late talc headlin
posit cautious optimist settlement opioid could occur
year market valu fundamentalswhich see posit
expect pe expand pharma continu grow market js devic
busi improv consum prune profit
what next talc-two thing feb fda conven meet discuss
test method talc see talc test showdown continu fda test
method meet feb reiter overweight note wont activ
particip convey test method exceed current fda standard
cosmet talc word advanc multi-district litig
daubert decis determin expert testifi case go
forward still day event specif rule deadlin insid
report background inform talc daubert hear
devic day may expect day highlight digital/robot surgeri
platform includ auri pend verb acquisit well veli
orthoped digit surgeri platform note strengthen digit surgeri
robot program verb jv buy-out anoth reason like
re-affirmed intent file us approv orthoped robot
support launch spring aao meet see event
catalyst improv confid medic devic segment
modestli updat estim modestli updat forecast
ep estim goe prior maintain price target
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
idc link barclay live interact chart
overweight believ share like
trade fundament next
month trade closer peers/market
believ fundament solid pharma growth
strong driven darzalex imbruvica
stelara tremfya portfolio move posit
medtech/consum allow least
market growth
upsid driver includ capit deploy drive
faster growth greater success new drug
outcom greater margin expans
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
action drug/devic recal margin eros
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
sale slightli street/our estim pharmaceut sale
organ continu strong in-lin estim medic devic
organ consum organ came bit lower expect
adjust ep bloomberg estim
expect organ sale growth includ net benefit
sell days/sku ration adjust ep net/net
invest view unchang continu rate share overweight
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
pharma organ came better robust sale growth continu
darzalex imbruvica tremfya stelara
help off-set pressur biosimilar gener
 expect pharma grow market driven continu strong sale
growth aforement key product well indic expans
 js major joint devic overal continu improv gener momentum
 host medic devic investor day may increas
investor confid abil compani acceler perform
ep guidanc came pre-result street
estim driven higher expect fx headwind said typic
provid conserv guidanc onset year
 anticip sku ration program consum segment result
slightli neg impact segment
 continu struggl spine declin us primari
driver magnitud declin partial due repeat one-tim
favor price relat true-up affect global growth
gross margin sale y/i
sg sale y/i reflect plan priorit
consum busi partial off-set increas invest medic devic
 sale y/i primarili driven slightli lower
mileston payment pharma partial off-set invest medic devic
oper margin y/i
adjust tax rate bp y/i
adjust ep street estim
estim
 give quarterli guidanc offer commentari note includ equiti gain relat
acquisit dr ci labo lead elev level incom manag also comment expect headwind sell
day impact medic devic sale major off-set
 guid adjust organ oper sale growth oper sale growth report
basi manag expect sale growth billion expect adjust oper margin improv
net interest expens million net incom billion effect tax rate
manag expect averag dilut share count line billion share adjust ep expect
includ neg fx impact reflect growth y/i
focu talc
 websit dedic inform talcum powder safeti legal updat
talc link asbesto
talc miner compos magnesium silicon oxygen hydrogen mine
earth chemic talc hydrou magnesium silic talc use cosmet
person care product includ js babi powder
talc safeti concern asbesto cancer new rather
concern nearli half centuri
asbesto also silic miner occur natur bundl fiber mainli
made silicon oxygen well element two main kind
asbesto link cancer accord american cancer
chrysotil asbesto also known white asbesto serpentin curli asbesto
common type industri applic fiber spiral
amphibol asbesto fiber straight needl like sever variou
form amphibol asbesto includ amosit brown crocidolit blue tremolit
actinolit anthophyillit
tremolit miner natur occur talc deposit talc
contain amphibol inosil miner name tremolit asbestiform
fibrou non-asbestiform cleavag fragment
fda conduct four-year intens investig issu
whether cosmet talc product includ js contamin asbesto
result investig fda conclud none talc use product
contain asbesto contamin
concern continu fda state reason put
warn label cosmet talc cite result studi on-going surveil
fda test raw talc four talc supplier includ js supplier
babi powder shower-to-show divest fda confirm
none contain asbesto
fda review relev bodi scientif literatur conclud
find data submit present conclus evid causal associ
talc use perin area ovarian cancer
cancer societi also opin topic physician data queri pdq
nation cancer institut comprehens sourc inform nci ovarian
fallopian tube primari periton cancer prevent pdq conclud weight
evid support associ perin talc exposur
increas risk ovarian cancer remain sceptic scienc studi
claim associ talc ovarian cancer
 note legal brief observ studi
numer meta-analys sever experiment studi publish issu
none studi purport establish causal link talc ovarian cancer
scientif commun taken posit
octob fda found asbesto disput find
octob announc receiv test report fda
show sub-trac amount chrysotil asbesto greater singl
bottl johnson babi powder purchas on-line retail voluntarili recal
lot bottl test sampl taken initi
investig identifi possibl sourc contamin believ
matter contamin given asbesto chrysotil form
octob subsequ announc new test bottl
previous test fda found asbesto addit bottl
lot also found asbesto test conduct behalf two third-parti lab
 also note expedit test third-parti deviat normal protocol
sampl contamin asbesto highlight import investig
posit result safeguard follow protocol
decemb issu final updat note test conduct two third-
parti lab show asbesto present singl bottl fda
contract lab ama analyt servic test present retain sampl
finish lot bottl produc moreov js investig reveal
test protocol fda contract lab ama deviat standard practic
ama execut full asbesto confirm requir lab test
method js press releas note js investig conclud probabl caus
fda result either sampl contamin and/or analyst error ama lab
 test test use four differ test method sampl
bottl test ama recal lot well three lot three lot
recal lot note result confirm asbesto also note rule
mine manufactur suppli chain root caus ama sub-trac find
feb fda conven meet discuss test method talc see
fda note meet topic includ scientif data inform relat
methodolog terminolog criteria use develop
standard test method improv sensit consist inter-laboratori
concurr asbesto test fda also seek comment sensit
plm test method includ whether test method lead fals neg
result asbesto particl sensit test method includ abil
test method identifi asbesto particl comparison plm criteria
identif specifi asbesto miner note differ miner
chemic composit exist sampl also seek comment valid
analyt method method sampl regist attend via person
webcast januari eastern time see detail fda webpag
see link note wont activ particip convey test method exceed
current fda standard cosmet talc word advanc
 face numer lawsuit claim bodi powder contain talc primarili
johnson babi powder caus cancer ovarian cancer mesothelioma
 js recent period end septemb disclos
plaintiff direct claim file lawsuit relat talc note
lawsuit relat talc primarili file state court missouri new jersey
california well outsid unit state case file us feder court
organ multi-district litig mdl unit state district court
district new jersey
figur list talc case date note success number case
includ last sever case also note success defend case upon
appeal fact everi case gone appeal process
await appeal believ strong ground overturn initi verdict
 establish accrual defens cost connect product
liabil litig associ bodi powder contain talc
notabl case lost far missourith ingham case includ
plaintiff out-of-st juri award plaintiff total million
compensatori damag billion punit damag total billion
accord juror punit damag calcul take roughli
million earn sell babi powder recent year multipli year
sinc compani claim babi powder contain asbesto see talc cancer
verdict billion st loui juri send power messag st loui post-
dispatch appeal case could heard appel level later
year like could fall
 talc tracker
jjcc plaintiff damag
citi
revers appeal
citi
revers appeal
citi
revers appeal
citi
citi
revers appeal
citi
appeal jnov affirm jj jnov
affirm punit jnov
revers jjci liabil juli
new trial jjci
appeal file
citi
plaintiff file appeal
compensatori
punit j/jjci resp
mcneil
jj/jjci
respons total
appeal file
appeal file
wait see plaintiff appeal mesothelioma
plaintiff seek new trial base
next mileston mdl
judg rule
expert present
bellweth case
expect day though
could also week
talc-rel lawsuit organ multi-district litig mdl
toxic tort caus injur parti respons prove injuri causat
prove causat plaintiff expert wit provid reports/testimoni
feder rule evid rule testimoni expert wit defin expert
wit wit qualifi expert knowledg skill experi train
educ may testifi form opinion otherwis
expert scientif technic special knowledg help trier
fact understand evid determin fact issu
testimoni base suffici fact data
testimoni product reliabl principl method
expert reliabl appli principl method fact case
daubert hear determin admiss expert wit testimoni
whether opinion suffici reliabl base sound scientif principl
allow juri consid evid
 motion exclud plaintiff expert daubert believ
plaintiff expert gener causat opinion plaintiff expert opinion relat
biolog plausibl expert opinion ghassan sa plaintiff expert
fragranc fibrou talc johnson babi powder shower shower and/or
expert opinion unrel gener causat also believ court exclud
opinion arguabl exceed plaintiff expert qualif
gener causat opinion seek exclud expert state perin
talcum powder use caus ovarian cancer claim methodolog flaw
bradford hill analys
biolog plausibl seek exclud expert opinion relat
biolog plausibl talc travel transport extern
perineum fallopian tube ovari talc caus chronic inflamm
ovari inflamm caus ovarian cancer
opinion ghassan sa ph claim dr sa experi
riddl error nonsens result gener sloppi unreli lab
notebook rife mathemat error white-out chang date miss
page led manuscript reject gynecolog oncolog journal
conclus suffici support dr sa ultim
publish similar draft reproduct health journal also note journal
articl fals claim dr sa receiv compens write manuscript
fact paid plaintiff counsel
asbestos-rel opinion relat opinion expert js babi powder
shower-to-show contain one time contain trace amount asbesto
princip propon theori plaintiff expert dr william longo
mark rigler also put testimoni dr robert cook mark krekel
categori well
heavi metal fragranc johnson babi powder shower-to-show
seek exclud expert opinion regard product may contamin
unspecifi amount chromium cobalt nickel metal
fibrou talc product fragranc ingredi could caus ovarian cancer
opinion unrel gener causat specif seek exclud plaintiff
expert whose report believ larg entir irrelev gener
expert due lack qualif seek exclud plaintiff expert
believ mani plaintiff expert seek offer opinion wide rang
subject fall outsid scope particular area expertis
 js summari tabl plaintiff counsel expert motion exclud base variou reason
court held daubert hear mid-juli attend hear
view js expert credibl plaintiff less plaintiff
submit final round brief court next mileston judg
rule expert present bellweth case expect day
though could also week
revenu breakdown divis
pre-tax profit breakdown divis
note pre-tax profit adjust exclud gain dr ci labo
equiti invest well gain sale asp busi
discuss herein
 js segment sale includ drug immun system
cardiovascular diseas metabol disord
pharmaceut sale total billion oper basi
exclud fx acquisitions/divestitur gener zytiga impact ww pharma growth
pharma growth led oncolog infecti diseas
immunolog neurosci cardiovascular/metabol sale
declin driven continu competit pressur label chang invokana
biosimilar competit procrit xarelto flat volum increas off-set
increas medicar util higher donut hole util rebat chang pulmonari
hypertens sale declin due impact one-tim distributor
model chang us
immunolog sale total million constant currenc basi
strong perform tremfya stelara well good growth
simponi off-set remicad declin due biosimilar competit
tremfya achiev psoriasi market us
file applic fda europ expand label indic includ
adult activ psoriat arthriti
stelara continu robust growth trajectori primarili driven crohn diseas
indic market share increas versu stelara
approv treatment moder sever activ ulcer coliti
european commiss septemb fda octob
oncolog sale constant currenc basi oncolog
growth driver though gener competit zytiga velcad recent
weigh perform
darzalex continu lead perform global growth us growth
broad-bas driven new front line indic multipl myeloma transplant
inelig popul growth also strong constant
currenc basi manag continu await approv subcutan
imbruvica grew global driven market share gain market growth primarili
chronic lymphocyt leukemia cll indic us well strong uptak
outsid us
 manag note continu pleas launch progress erleada
erleada approv metastat castration-sensit prostat cancer mcspc well
million sale million full year primarili us
zytiga sale declin reflect continu impact gener us busi
offset intern growth velcad sale also
reflect impact gener
neurosci sale million constant currenc basi led
paliperidon long-act portfolio includ invega sustenna xeplion invega trinza
trevicta constant currenc basi
 provid sale contribut commentari spravato manag
note new patient start continu steadili increas patient
treat date decemb spravato approv europ adult treatment
resist major depress disord view payor coverag may limit factor
uptak product
pulmonari hypertens sale million declin reflect mainli impact
distributor model chang us impact sale growth
opsumit uptravi continu drive share growth global sale growth exclud
distributor model impact respect growth partial off-set
declin sale tracleer due continu gener competit
infecti diseas sale million grew constant currenc basi driven
strength symtuza juluca hiv partial off-set cannib well gener
competit product
cm sale total million declin constant currenc basi
declin function three key drug
procrit/eprex sale declin due continu biosimilar competit
invokana sale declin due share loss competit pressur safeti
label updat us
xarelto sale flattish volum increas off-set increas
medicar util higher donut hole util rebat chang
pharmaceut recent approv outlook
look ahead expect grow franchis overal pharma market estim
grow around
diabet kidney diseas heart failur hospit type diabet patient
venou thromboembol vte acut ill medic patient
submit fda
submit ema
sbla submit
treatment adult patient moder sever activ ulcer coliti
treatment pediatr patient age moder sever plaqu psoriasi
treatment patient moder sever activ ulcer coliti
treatment adult patient live activ psoriat arthriti
treatment adult activ psoriat arthriti
submit ema
treatment adult major depress disord current suicid ideat
treatment adult live treatment-resist major depress disord
combin regimen bortezomib thalidomid dexamethason treatment
newli diagnos transplant-elig patient multipl myeloma
combin regimen lenalidomid dexamethason treatment newli
diagnos transplant-inelig patient multipl myeloma
combin regimen newli diagnos stem cell transplant-elig patient
submit ema
fda
treatment patient metastat castration-sensit prostat cancer mcspc
combin rituximab previous untreat patient cll
combin rituximab previous untreat patient cll sll
expand use combin obinutuzumab adult patient previous untreat
cll combo rituximab waldenstrom macroglobulinemia
pharmaceut event
major depress disord activ suicid ideat
frontlin cll combo rituximab young fit
subcutan formul patient relaps refractori
treatment diabet kidney diseas adult
monotherapi multipl sclerosi
major depress disord activ suicid ideat
relaps refractori multipl myeloma pomdex
frontlin cll combo rituximab young fit
-refractori multipl myeloma pomdex apollo
 js medic devic segment sale includ product use orthoped
surgeri intervent solut eye health
total segment sale adjust fx acquisition/divestitur grew
note one-tim item mainli relat consumpt tax chang japan
neg affect growth quarter manag note sell day
immateri impact
orthoped sale constant currenc basi product line like
us knee hip continu show sign improv price trend remain
neg though show modest improv rel recent trend spine
y/i trauma hip knee flat
hip grew oper took share due anterior approach offer well
demand acti primari stem enabl technolog
knee growth driven strong perform new offer attun
revis attun attun cementless rotat platform notabl us knee
busi return growth quarter albeit
manag re-affirmed intent file orthoped digit surgery/robot
platform velys/orthotaxi allow launch conjunct
american academi orthoped surgeon confer new
product launch decemb launch veli digit surgeri platform
initi focus includ joint reconstruct technolog like kincis system
jointpoint kincis surgic autom system design improv precis
jointpoint system design analysi implant select posit
non-invas comput navig pre-surg digit templat case plan
note time includ new technolog orthotaxi robot solut
patient select tool advanc visual sensor app
trauma growth global driven market growth well uptak new
product femor neck system
spine sale declin global part driven difficult comp
year ago quarter includ one-tim favor pricing-rel true neg
impact global growth comment see posit uptak new
product symphoni surgic system posterior cervic spine procedur
surgeri sale declin oper basi due asp divestitur
organ basi estim sale increas
advanc surgeri deliv growth driven strong intern growth
partial off-set us declin surgiflo continu ramp back
growth driven aspac share gain market growth biosurgeri well
strength energi endocutt
gener surgeri growth rel flattish strength wound closur
china well share gain convent barb sutur growth
help off-set declin us
manag note continu believ long-term strategi digit surgeri
plan provid detail upcom medic devic day may
includ auri monarch system well pend verb surgic joint ventur buy-
note strengthen digit surgeri robot program verb jv buy-out
anoth reason like
electrophysiolog well double-digit growth cerenovu driven strong
market growth new product innov includ embotrap ischem stroke
manag also highlight newer product offer ablat advanc cathet
contribut atrial fibril af procedur market growth
vision sale growth adjust neg impact japan
consumpt tax forward buy growth primarili driven contact lens
adjust japan consumpt tax led double-digit growth daili
dispos oasi famili
surgic vision sale bit tale two citi us
busi reflect competit pressur lower growth refract
surgeri busi driven cataract busi
primarili asia pacif
 js consum segment sale includ product babi care oral care
beauti over-the-counter women health wound care market
segment grew exclud impact fx acquisitions/divestitur
beauti sale grew exclud impact dr ci labo
acquisit roc divestitur neutrogena growth outsid us driven anti-ag
cleans emea hand bodi moistur strength asia pacif
usshar growth larg off-set anniversari prior year new product pipelin
build higher trade invest
over-the-counter sale grew strength us reflect share growth multipl product
adult tylenol pepcid zarbe us growth also aid
stock due increment distribut trade promot program intern
babi weak continu busi declin
exclud impact babycent divestitur declin due continu
competit pressur well expect difficult comparison retail stock
associ johnson babi relaunch us
detail confer call pleas see note
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
